1. Home
  2. About Us
  3. News
  4. Latham Advises Novo Holdings on Quanta’s US$245 Million Series D Fundraising

Latham & Watkins Advises Novo Holdings on Quanta’s US$245 Million Series D Fundraising

London corporate team counsels on largest-ever private funding round for a dialysis device company.

June 24, 2021

Latham & Watkins advised Novo Holdings on co-leading a US$245 Million Series D funding round for Quanta Dialysis Technologies, a medical technology leader delivering on its vision for more flexible and accessible dialysis care.

The round was co-led by hedge fund Glenview Capital, with support from a broad group of other top-tier investors, including BlackRock, Eldridge, Sands Capital, Millennium, Monashee Investment Management LLC., Puhua Capital, Segulah Medical and Ancora, alongside Orlando Health, an integrated delivery network. Existing shareholders also participated in the round, including Wellington Partners, btov, Seroba and The Grands.

The Latham team was led by London corporate partner Robbie McLaren, with associate Samantha Peacock. Advice on life science matters by was provided by associates Frances Stocks Allen, Sara Patel, and Oscar Bjartell; and on employment matters by associates Adam Ray and Kendall Burnett. 

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.